John Hertia, President-Clinical Diagnostics Group, Bio-Rad Laboratories

"Amplichek II quality control complements already extensive range of quality controls and reflects commitment to offer innovative products that help improve laboratory analytical performance."

John Hertia
President-Clinical Diagnostics Group,
Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. has entered into the rapidly growing molecular diagnostics testing market with the launch of Amplichek II quality control, which was recently issued a de novo clearance from the US FDA. It is an independent, multi-analyte quality control that monitors the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of healthcare-associated infections. The quality control began shipping in May and is the first in a series of infectious disease controls that Bio-Rad plans to introduce for the molecular diagnostic testing market.


A New Cancer Treatment

10 Unbelievable Innovation in Medicine

 

Digital version